Key terms
About AXSM
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AXSM news
Today
2:56am ET
Auvelity’s Strong Performance Sustains Buy Rating for Axsome Therapeutics
Apr 08
10:10pm ET
Analysts Offer Insights on Healthcare Companies: Surrozen (SRZN), Exelixis (EXEL) and Axsome Therapeutics (AXSM)
Apr 02
6:26am ET
Buy Rating Affirmed for Axsome Therapeutics Amid Strong Clinical Pipeline and Market Expansion Potential
Apr 01
7:17am ET
Axsome Therapeutics initiates ENGAGE Phase 3 trial of solriamfetol
Mar 28
6:39am ET
Axsome Therapeutics price target raised to $109 from $108 at Mizuho
Mar 26
8:45am ET
Truist Financial Remains a Buy on Axsome Therapeutics (AXSM)
Mar 26
6:40am ET
Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Axsome Therapeutics (AXSM) and Sotera Health (SHC)
Mar 26
6:16am ET
Buy Rating Affirmed for Axsome Therapeutics with Increased Target Price Following Strong AXS-12 Trial Results
Mar 26
4:55am ET
Maintaining Hold on Axsome Therapeutics: Weighing AXS-12’s Modest Efficacy Against Competitive and Market Risks
Mar 25
9:20pm ET
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Sensei Biotherapeutics (SNSE)
Mar 25
7:05am ET
Axsome Therapeutics announces results of CRESCENDO narcolepsy survy
Mar 25
6:34am ET
Axsome Therapeutics says AXS-12 achieves primary endpoint in SYMPHONY trial
Mar 20
6:30am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 19
7:03am ET
Axsome Therapeutics initiates PARADIGM Phase 3 trial of Solriamfetol
Mar 19
1:37am ET
Axsome Therapeutics’ Auvelity Rebounds: A Buy Rating Reinforced by Prescription Growth and Market Resilience
Mar 18
4:33pm ET
Axsome Therapeutics initiated with an Outperform at Baird
Mar 13
2:40am ET
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Axsome Therapeutics (AXSM)
Mar 08
7:25am ET
TD Cowen Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)
Mar 05
1:26am ET
Axsome Therapeutics Maintains Buy Rating Amid Temporary Disruption
Mar 04
12:20am ET
5 Best Biotech Stocks to Buy Now, According to Analysts – March 2024
Feb 27
7:47am ET
Axsome Therapeutics (AXSM) Receives a Buy from Truist Financial
Feb 27
6:36am ET
Axsome Therapeutics price target lowered to $108 from $112 at Mizuho
Feb 22
12:56am ET
Buy Rating Affirmed for Axsome Therapeutics Amid Strong Financials and Promising Pipeline
Feb 22
12:20am ET
Analysts Are Bullish on These Healthcare Stocks: Edgewise Therapeutics (EWTX), Bicycle Therapeutics (BCYC)
Feb 21
7:58am ET
Axsome Therapeutics price target lowered to $123 from $126 at RBC Capital
Feb 21
7:20am ET
Analysts Conflicted on These Healthcare Names: NeoGenomics (NEO), Axsome Therapeutics (AXSM) and Medtronic (MDT)
Feb 21
7:16am ET
Axsome Therapeutics price target lowered to $107 from $111 at UBS
Feb 21
7:11am ET
Axsome Therapeutics price target raised to $125 from $110 at Guggenheim
Feb 20
4:45pm ET
Axsome Therapeutics Updates Corporate Presentation Online
Feb 20
11:25am ET
Buy Rating Affirmed for Axsome Therapeutics on Strong Auvelity Sales and Promising Pipeline Outlook
Feb 20
7:09am ET
Axsome Therapeutics reports Q4 EPS ($2.08), consensus ($1.17)
No recent press releases are available for AXSM
AXSM Financials
Key terms
Ad Feedback
AXSM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AXSM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
